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Effect of thrombin on cyclic AMP content in glomeruli isolated from rat
kidney. Localized thrombin-mediated intravascular coagulation has
been implicated as an important pathogenetic factor in a variety of
glomerular and vascular diseases of the kidney. Recent studies indicate
that glomerular function is affected by several hormonal agents which
alter the cyclic AMP or cyclic GMP content in the glomeruli. Although
thrombin has been shown to affect several metabolic processes in other
cellular systems the possibility that thrombin may cause a reduction in
glomerular function by altering cyclic nucleotide metabolism has not
been previously considered. We therefore examined the effect of
thrombin on the cyclic AMP and cyclic GMP content in glomeruli
isolated from rat renal cortex. Thrombin caused a dose dependent (0.01
to 1 U/mI) increase in the cyclic AMP content in the glomeruli but had
no effect on the cyclic GMP content. The effect was first observed at 30
seconds and reached a peak at five minutes. Tubules isolated from the
same rats had no response to thrombin. The glomerular cyclic AMP
response to thrombin inactivated with diisopropylfluorophosphate was
markedly impaired, indicating the requirement for the protease activity
of thrombin for the observed effect. Thrombin did not affect the cyclic
AMP phosphodiesterase activity in glomeruli. Thrombin-mediated in-
crease in glomerular cyclic AMP may play an important role in the
reduction in glomerular function that is observed in a variety of
glomerular and vascular renal diseases in which intravascular coagula-
tion plays a prominent role.
Recent studies indicate the importance of glomerular cyclic
nucleotide metabolism in glomerular pathophysiology [1—4].
For example, glomerular function has been shown to be af-
fected by several hormonal agents which alter the cyclic AMP
or cyclic GMP content in the glomeruli [1—31. In addition, the
cyclic nucleotide content in the glomeruli is altered most
strikingly by several well-known mediators of inflammation
including histamine [1, 21, serotonin [1, 21, and prostaglandins
11, 21 and reactive oxygen metabolites [5]. Extensive experi-
mental evidence that cyclic AMP and cyclic GMP modulate
inflammatory and immune responses in various tissues [2, 6, 7]
suggests a similar role for cyclic nucleotides in glomerular
disease.
The coagulation process including platelet aggregation and
localized intravascular coagulation has been implicated as a
primary pathogenetic factor or a secondary mediator of injury
in a variety of glomerular and vascular diseases of the kidney
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[reviewed in 8 and 9]. Evidence supporting such a role includes:
the demonstration of fibrinoid material in the glomeruli by light,
electron, and immunofluorescence microscopy; the presence of
altered fibrinogen metabolism and altered platelet survival in
patients with glomerulonephritis; and the detection of fibrin
degradation products in the serum and urine of patients with
glomerulonephritis. Thus current evidence suggests a promi-
nent role of platelet aggregation and intravascular coagulation
in several renal diseases including hemolytic uremic syndrome,
pre-eclampsia and hyperacute renal allograft rejection. These
glomerular and vascular diseases are characterized by a marked
reduction in glomerular function. However, the mechanism/s
responsible for the reduction in glomerular function in these
glomerular and vascular diseases of the kidney is unknown. The
possibility that the coagulation factors and/or platelets cause a
reduction in the glomerular function by altering glomerular
metabolism has not been previously considered.
Thrombin, the serine protease that converts fibrinogen to
fibrin, is well known to affect platelet function and, more
recently, has been shown to alter endothelial function. The
effects on endothelial cells include enhanced release of prosta-
cyclin [10, 111 and von Willebrand factor [12], thrombomodulin-
mediated activation of protein C [131, and enhanced release of
tissue-type plasminogen activator antigen and fast-acting plas-
minogen inhibitor [14]. Thrombin has also been shown to
increase cyclic AMP content in fibroblasts [15] and to increase
the cyclic OMP content in munne neuroblastoma cell [16].
However, the effect of thrombin on the cyclic AMP and cyclic
GMP content in glomeruli has not been previously examined.
Methods
Isolation of glomeruli
Glomeruli and tubules were isolated from kidneys obtained
from Sprague-Dawley rats by a combination of sieving and
differential centrifugation as described in detail in our previous
study [5, 171. Sprague-Dawley rats that weighed 200 to 250 g
were anesthetized with pentobarbital (50 mg/kg) and a polyeth-
ylene catheter (PE 100) was inserted into the lower abdominal
aorta immediately above the bifurcation. Subsequently, the
aorta was clamped above the renal arteries, the renal veins were
cut, and the kidneys were perfused with ice-cold Hank's
balanced salt solution (HBSS). After the kidneys were
blanched, they were removed and decapsulated. Kidneys that
did not blanch well were discarded. All subsequent preparative
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steps were carried out at 4°C. The cortex was carefully dis-
sected, minced with a blade, and gently squeezed through a
stainless steel sieve (250 M opening) using a metal spatula. The
resulting suspension of cortical tissue was washed four times in
the buffer by repeated centrifugation at 200 g for two minutes to
eliminate small fragments in the supernatant. The resultant
pellet was resuspended in buffer and passed sequentially
through Nitex nylon sieves (Tetko Inc., Elmsford, New York,
USA) of 390-, 250-, and l80-M pore openings. The particles
retained on the 390- and 250-tiM sieve consisted of tubular
fragments and were collected as a tubular fraction. This tubular
fraction, referred to later in the text as "tubules", was washed
again on the 250-MM nylon screen with HBSS to reduce
glomerular contamination to a negligible level. To obtain gb-
meruli, the suspension resulting after filtering through 180 M
sieve was passed through a screen cloth (Nitex No. 25, —80 LM
pore opening); this step allowed debris and small fragments to
pass through, with glomeruli retained on the cloth. The retained
glomeruli were recovered by gently rinsing with buffer. Both
glomerular and tubular preparations were transferred to pre-
weighed polyalbomer tubes, and were centrifuged at 1,500 g for
five minutes; the supernatant was removed by aspiration, and
the tubes were weighed again to determine approximate wet
weight of the preparations. Glomeruli or tubules were sus-
pended in fresh HBSS so that --20mg (wet wt) of glorneruli and
40 mg of tubules were contained in 1 ml of HBSS suspension.
The purity of each preparation was evaluated by counting
glomeruli under light microscopy; only preparations with
greater than 90% purity were used. It must be emphasized that
whereas the glomerular preparation is relatively homogeneous,
the tubular fraction consists of diverse tubular segments from
the renal cortex.
Incubations and assays for cyclic AMP
Incubations and analysis of cyclic nucleotides were con-
ducted as described in our previous studies [5, 17]. Freshly
prepared glomeruli (4 to 6 mg, wet wt) and tubules (8 to 12 mg,
wet wt) were first distributed randomly (in triplicate) into glass
homogenizer tubes kept in crushed ice at 0°C, and then pre-
incubated at 37°C for 20 minutes in a Dubnoff metabolic shaking
water bath. At the end of the pre-incubation period, 1-methyl-
3-isobutyl xanthine (MIX) was added to all tubes. Thrombin or
buffer were added at the same time. The final volume of each
suspension was then 0.5 ml, with 0.5 mis-i MIX, and the final
concentration of thrombin as indicated in Results. The tubes
were incubated for an additional five minutes at 37°C in a
metabolic shaking water bath. The incubation was terminated
by adding 0.5 ml of ice-cold 10% trichloroacetic acid and
homogenizing immediately with a Teflon pestle. After adding
tracer amounts of tritiated cyclic AMP, and in some experi-
ments, tritiated cyclic GMP to aliquots for monitoring recovery,
the precipitated proteins were removed by centrifugation. Tn-
chloroacetic acid was removed from the supernatant by re-
peated extraction (X4) with ethyl ether; the remaining ether was
heat evaporated, and the samples were used for determinations
of cyclic nucleotides by radioimmunoassay (RIA) and for
measurements of recovery. Samples from each experiment
were processed (extraction, RIA, and protein determination) at
the same time, using the same batch of reagents.
The RIA for cyclic AMP and cyclic GMP was carried out in
triplicate in acetylated samples, exactly as described in the New
England Nuclear RIA kits (Boston, Massachusetts, USA). The
protein content was determined by the Biorad method (Rich-
mond, California, USA) in aliquots of glomeruli and tubules
from the same incubations as those used for measurements of
cyclic nucleotide content. Because glomeruli and tubules were
homogenized together with the incubation medium, the content
of cyclic AMP and cyclic GMP represents the sum of the cyclic
nucleotides contained within cells and in the incubation me-
dium. After correction for recovery the content of cyclic AMP
and cyclic GMP in samples was expressed as picomoles per mg
of protein in the incubation mixture. None of the agents used in
the study interfered with the cyclic AMP measurements.
Incubations and assays for cyclic AMP phosphodiesterase
To examine the effect of thrombin on cyclic AMP phospho-
diesterase activity in glomeruli, after a 20 minute pre-incubation
at 37°C, thrombin (1 NIH U/ml) or buffer was added and the
tubes (with a final volume 0.5 ml) were incubated for an
additional five minutes at 37°C in a metabolic shaking water
bath. At the end of the incubation, the tubes were centrifuged,
the incubation buffer rapidly removed, the glomeruli homoge-
nized with ice-cold homogenization medium, and rapidly frozen
with dry ice. The homogenization medium had the following
composition: 0.25 M sucrose, 10 mM Tris, 5 mrs-i magnesium
chloride, 0.2 mrs-i ethyleneglycol-bis (/3-amino-ethyl-ether)-
N,N,N',N'-tetraacetic acid (EGTA), 100 nM leupeptin, 100 nrvi
pepstatin A, 100 nM phenylmethanesulfonyl fluoride (PMSF)
and 1% triton.
Measurement of the cyclic AMP phosphodiesterase activity
was carried out as previously described [18] by incubating
glomerular homogenates (in quadruplicate for each sample) in
assay medium at 30°C for 15 minutes with a final substrate
concentration of 1 /LM 3H-cyclic AMP (20 x l0 cpm). The
assay medium consisted of 10 m magnesium sulfate, 50 mrs-i
Tris hydrochloric acid (pH 8.0). The results were expressed in
pmol/mg/min.
Materials
Synthetic 1,34-N-terminal tetratriacontapeptide of parathy-
roid hormone (6,000 U/mg) was purchased from Beckman
Instruments, Inc. (Bioproducts, Spinco Div., Palo Alto, Cali-
fornia, USA), and 1-methyl-3-isobutyl xanthine from Aldrich
Chemical Co., Inc. (Milwaukee, Wisconsin, USA). Hank's
balanced salt solution (450-1201) was from Grand Island Bio-
logical Company, Grand Island, New York, USA. Tritiated
cyclic AMP, tritiated cyclic GMP, and the RIA kits for cyclic
AMP and cyclic GMP were obtained from New England
Nuclear. All other reagents, and chemicals including soya bean
trypsin inhibitor (Type 1-S; chromatographically prepared),
trypsin (E C3.4.21.4, from bovine pancreas, DPCC treated type
XI, 7150 BAEE units per mg) and highly purified (essentially
free of other clotting factors as well as plasminogen and
plasmin) a-thrombin (EC 3. 4. 21. 5, human plasma, 3600 NIH
U/mg protein) were from Sigma Chemical Co., St. Louis,
Missouri, USA. Nylon screens for sieving were from Tetko,
Inc. Thrombin was inactivated as previously described [11] by
incubation with diisopropylfluorophosphate (DFP) 10 mrs-i for 30
minutes at room temperature followed by overnight dialysis to
remove excess DFP. The effect of DFP-treated thrombin was
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Fig. 1. Time course of the effect of thrombin (0.1 NIH U/mi) on the
cyclic AMP content in glomeruli. Each point represents the mean
SEM of three samples. The incubations were carried in the presence of
MIX, a phosphodiesterase inhibitor.
compared to the effect of native thrombin that had been
similarly dialyzed. The inactivation of thrombin by DFP was
confirmed by the clotting assay using Fibrometer (Becton,
Dikinson and Co., Cockeyville, Maryland, USA).
Results
We first examined the time course of the response of glomer-
ular cyclic nucleotide content to thrombin, because the re-
sponse of cyclic GMP may be early and transient and may not
be detected unless measured at several time points. As in our
previous studies 5, 17], these incubations were carried out in
the presence of l-methyl-3-isobutyl xanthine, an inhibitor of
cyclic AMP, and cyclic GMP phosphodiesterase, in order to
optimize conditions for detecting increases in the cyclic nude-
otides. As shown in Figure 1, an increase in cyclic AMP was
first noted at 30 seconds, the earliest time point examined, and
reached a peak at five minutes. In the same experiments no
changes in cyclic GMP content in the glomeruli were observed
at any of the time points examined. This was not due to lack of
responsiveness of the glomeruli because in the same experi-
ments, nitroprusside (1 mM) caused a marked increase in the
cyclic GMP content in the glomeruli (data not shown).
The effect of various concentrations of thrombin on the cyclic
AMP and cyclic GMP content in glomeruli was also examined.
The glomerular cyclic AMP response to thrombin (value in the
presence of thrombin minus the value in the absence of throm-
bin) is shown in Figure 2. Thrombin, in a concentration of 0.01
U/mI caused a significant increase, with linear increase in the
cyclic AMP content in glomeruli up to 1.0 U/mI, the highest
concentration examined. Thrombin in the same concentrations
had no effect on the cyclic GMP content in the glorneruli
(control: 1.8 0.47; thrombin (1 IJ/ml): 1.7 0.33 pmol/mg
protein, N = 3).
Thrombin, U/mi
Fig. 2. Effect of thrombin on the cyclic AMP content in glomeruli.
Each point represents the mean SCM of the glomerular cyclic AMP
response (value in the presence of thrombin minus the value in the
absence of thrombin). The incubations were carried in the presence of
MIX, a phosphodiesterase inhibitor. Thrombin in the same concentra-
tions had no effect on the cyclic GMP content in glomeruli.
Table 1. Effect of thrombin on cyclic AMP content in glomeruli and
tubules
N
Cyclic AMP
pmol/mg protein
z
increase
%
change
Glomeruli
Control 13 15.5 1.3
Thrombin 13 41.7 2.8a 26.2 2.4a 184 22°
Tubules
Control 3 3.8 0.3
Thrombin 3 4.8 1.1 0.9 1.4 31 41
Values are mean SCM. N = number of experiments each performed
in triplicate. Glomeruli or tubules were incubated at 37°C with thrombin
(1 NIH U/mI) or without thrombin (control) for five miuntes as
described under Methods. The incubations were carried out in the
presence of MIX, a phosphodiesterase inhibitor.
Value in presence of thrombin — control
xlOO
control
P < 0.001 or greater level of significance using the paired Student's
1-test
40 -
20
10
0)
0
E0.0
4Q
Q>0
(9)
5)
0.
0)
0
E0.0
4
C,
C)
>-0
(9)
(6)
30 -
20
10
0 I
0.01 0.1 1.0
(3)
0 2 4 6 8 10
The effect of thrombin on the cyclic AMP content in glomer-
uli was then compared to their effect on tubules isolated from
the same rats. In contrast to the marked effect on the cyclic
AMP content in the glomeruli, no effect on the cyclic AMP
content in the tubules was observed (Table 1). As in our
previous studies [5] parathyroid hormone caused a marked
increase in the cyclic AMP content in the tubules (data not
shown).
As described above, the incubations were carried out in the
presence of MIX to optimize the conditions for detecting the
changes in the cyclic nucleotides. In a few experiments we
examined the effect of thrombin on the cyclic AMP content in
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Fig. 3. The effect of thrombin (1 NIH U/mi) on glomerular cyclic AMP
content in the absence of a phosphodiesterase inhibitor. Values shown
are the mean SEM of three separate experiments each carried out in
triplicate. % increase: (value in presence of thrombin)-control value
(in the absence of thrombin)/control value x 100. % increase was 178
46, (*) <0.01.
the glomeruli in the absence of MIX. As expected, the cyclic
AMP values in the glomeruli were much lower in the absence of
MIX (Fig. 3) compared to the values obtained in the presence of
MIX. In the absence of MIX, the cyclic AMP content in the
glomeruli increased from 6.7 0.4 to 18.9 4.2 pmol/mg
protein, representing a A% increase of 178 46, N = 3 (Fig. 3).
Thus even in the absence of a phosphodiesterase inhibitor, the
effect of thrombin on the cyclic AMP content in the glomeruli
could be demonstrated.
We examined whether protease activity of thrombin is re-
quired for increasing the cyclic AMP content in glomeruli.
Thrombin was inactivated by treatment with DFP (with re-
moval of unreacted DFP by dialysis), an irreversible inhibitor of
thrombin and other serine proteases. As shown in Figure 4 the
glomerular cyclic AMP response to DFP-treated thrombin was
markedly impaired compared to native thrombin (that had been
similarly dialyzed) indicating that the protease activity is re-
quired for the observed effect. Because other serine proteases,
trypsin and chymotrypsin have been shown to increase cyclic
AMP in other tissues [19, 20] we examined the effect of trypsin,
an enzyme that is structurally similar to thrombin on glomerular
cyclic AMP content. Trypsin, in concentrations similar to those
used in previous studies [20], caused a marked increase in the
glomerular cyclic AMP content (A increase, trypsin (200 rg/ml):
Control Dialyzed DFP-
thrombin thrombin
Fig. 4. The effect of DFP-treated thrombin on the glomerular cyclic
AMP content in giomeruli. Thrombin was inactivated by incubation
with diisopropylfluorophosphate (DFP) 10 m for 30 minutes at room
temperature followed by overnight dialysis to remove excess DFP, and
its effect was compared to thrombin (1 NIH unit/mi) that had been
similarly dialyzed. The incubations were carried in the presence of
MIX, a phosphodiesterase inhibitor. Values shown are the mean SEM
of three separate experiments each carried out in triplicate. %
inhibition: (the cyclic AMP response to DFP-thrombin — the cyclic
AMP response to dialyzed thrombin/the response to dialyzed thrombin)
x 100. To measure the response, the control values of cyclic AMP were
subtracted from the values in presence of either DFP-treated or
dialyzed thrombin. 1% inhibition was 70 6, (*)P < 0.01.
41.9 6.1 pmol/mg protein, N = 6). Soya bean trypsin inhibitor
(SBTI, twofold wt/wt excess) markedly inhibited the response
(A increase, trypsin + SBTI: 7.8 4.6, pmol/mg protein, N =
5).
It is unlikely that the effect of thrombin on glomerular cyclic
AMP content was due to "contamination" by other proteases
and that the effect of DFP was on the "contaminating" prote-
ases because the amount of thrombin added was very small
(less than one-half tgIm1). Nonetheless, we examined the effect
of soya bean trypsin inhibitor (SBTI) on thrombin-induced
increase in glomerular cyclic AMP. SBTI (100 ig/ml) which
inhibits trypsin, chymotrypsin and plasmin but does not affect
thrombin [21], had no significant effect on the glomerular cyclic
AMP response to thrombin (A increase, thrombin 1 U/mI: 21.9
2.1 pmol/mg protein, N = 3, thrombin + SBTI: 25.2 1.1
pmol/mg protein, N 3).
Recent studies have indicated that the phosphodiesterases
constitute a complex group of enzymes [22], multiple forms of
which are found in most mammalian tissues. Importantly,
recent studies have documented hormonal regulation of cyclic
AMP phosphodiesterases [23, 24]. In view of these studies, in
separate experiments we also examined the effect of thrombin
on the cyclic AMP phosphodiesterase activity in glomeruli. As
shown in Table 2 thrombin had no significant effect on the cyclic
AMP phosphodiesterase activity in glomeruli.
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Table 2. Effect of thrombin on cyclic AMP phosphodiesterase
activity in glomeruli
Cyclic AMP p
pmollmin
hosphodiesterase
1mg protein
Control Thrombin
Experiment 1 68.5 74.9
Experiment 2 100.9 84.6
Experiment 3 93.9 85.0
Experiment 4 118.4 108.3
Mean 94.8 88.2
SEM 10.9 7,1
Glomeruli were incubated at 37CC with thrombin (I NIH U/mI) or
without thrombin (control) for five minutes as described under Methods.
The mean values from triplicate incubations are shown for each
experiment. The mean value in presence of thrombin is not significantly
different from control mean value when compared with either an
unpaired or paired Student's t-test.
ular function, thrombin-induced increase in cyclic AMP may
modulate inflammatory and immune responses in glomerular
disease.
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